$ENTX PT 6-10 and higher

NASDAQ:ENTX   Entera Bio Ltd
Entera Bio Ltd ., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc . for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd . was incorporated in 2009 and is based in Jerusalem, Israel.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.